发布求助
文献互助 智能选刊 最新文献

La Revue du praticien最新文献

筛选
英文 中文
[Metabolic dysfunction associated steatohepatitis, epidemiology and definitions: from steatosis to cirrhosis]. [脂肪性肝炎相关的代谢功能障碍，流行病学和定义：从脂肪变性到肝硬化]。
La Revue du praticien Pub Date : 2026-04-01
Raluca Pais
{"title":"[Metabolic dysfunction associated steatohepatitis, epidemiology and definitions: from steatosis to cirrhosis].","authors":"Raluca Pais","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A recent change in terminology proposed by scientific societies replaces the term NAFLD (non-alcoholic fatty liver disease) with the term MASLD (metabolic dysfunction associated steatotic liver disease). The prevalence of metabolic steatosis in France is 18.2%, higher among at-risk individuals (obese, diabetic, or with elevated transaminases). Among patients with MASLD, approximately 25% have liver inflammation with hepatocyte damage, now referred to as MASH (Metabolic dysfunction Associated Steatohepatitis), replacing the former name NASH (Non Alcoholic Steatohepatitis). MASH is associated with a significant increase in overall mortality, related to the severity of histological lesions, particularly cirrhosis. Cirrhosis develops in 15% to 30% of patients with MASH, usually at an older age than in other chronic liver diseases, due to a slower progression rate of fibrosis. Closely related to metabolic syndrome and insulin resistance, the disease progression involves the liver (progression of fibrosis, development of cirrhosis) but also exposes individuals to a significant risk of extrahepatic complications, such as cardiovascular, metabolic, and neoplastic diseases.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"388-392"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Steatosis and steatohepatitis: a risk factor for complications after liver resection]. 脂肪变性和脂肪性肝炎：肝切除术后并发症的危险因素。
La Revue du praticien Pub Date : 2026-04-01
Karim Boudjema, Fabien Robin, Heithem Jeddou, Pauline Houssel-Debry
{"title":"[Steatosis and steatohepatitis: a risk factor for complications after liver resection].","authors":"Karim Boudjema, Fabien Robin, Heithem Jeddou, Pauline Houssel-Debry","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), have become common clinical conditions in everyday practice. Long regarded as benign, they can lead to serious liver complications, including cirrhosis and hepatocellular carcinoma, which may require liver resection or, in selected cases, liver transplantation.The presence of steatosis or steatohepatitis increases the risk of postoperative complications after hepatic resection. In the transplant setting, MASH is an increasingly frequent indication and is reshaping the management of liver transplant recipients, who often have associated metabolic syndrome (obesity, diabetes, hypertension). After transplantation, recurrence of steatosis in the graft is almost inevitable, likely reflecting the persistence of underlying genetic and environmental factors that drive metabolic syndrome.At the same time, the rising prevalence of steatosis in the general population also affects organ donors, potentially impairing graft quality and complicating post-transplant management.The growing burden of MASLD and MASH therefore calls for close collaboration between hospital-based specialists and primary care physicians, particularly for screening, management of metabolic risk factors, and long-term follow-up of patients who have undergone liver surgery or transplantation.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"413-417"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[FIB-4: a simple blood test to identify patients at risk of liver complications]. [FIB-4：一种简单的血液检查，用于识别有肝脏并发症风险的患者]。
La Revue du praticien Pub Date : 2026-04-01
Jérôme Boursier, Frédéric Oberti
{"title":"[FIB-4: a simple blood test to identify patients at risk of liver complications].","authors":"Jérôme Boursier, Frédéric Oberti","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"398-399"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Current and future medical treatments for metabolic dysfunction-associated steatohepatitis]. [代谢功能障碍相关脂肪性肝炎的当前和未来医学治疗]。
La Revue du praticien Pub Date : 2026-04-01
Rodolphe Anty, Marwin A Farrugia
{"title":"[Current and future medical treatments for metabolic dysfunction-associated steatohepatitis].","authors":"Rodolphe Anty, Marwin A Farrugia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Drug treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) is undergoing a revolution. The fight against cardiovascular risk factors, the optimization of the treatment of type 2 diabetes, the screening of common extra-hepatic cancers, personalized dietary measures, therapeutic physical exercise programs and the fight against a sedentary lifestyle remain fundamental to propose to all patients. For patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis (F2-F3), resmetirom is the first effective and well-tolerated drug marketed in the USA and Europe. Semaglutide or double or triple incretin receptor/glucagon receptor agonists could constitute the future cornerstone of drug management for patients with MASLD, due to the achievement of very significant weight loss (from 10 to more than 24% of the initial weight). Semaglutide has been shown to reduce cardiovascular and renal events, and has been approved for marketing in the USA, for MASH without cirrhosis. The choice of the best drug combination, the optimal prescription duration and the best drug option in the case of MASH-related cirrhosis remain to be determined.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"400-408"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Healing Gods in India]. [印度的治愈之神]。
La Revue du praticien Pub Date : 2026-04-01
Philippe Charlier, Saudamini Deo
{"title":"[Healing Gods in India].","authors":"Philippe Charlier, Saudamini Deo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"381-383"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Being an influential doctor in 2026: what are the legal guidelines?] [2026年成为一名有影响力的医生：法律准则是什么？]］
La Revue du praticien Pub Date : 2026-04-01
Marianne Lahana
{"title":"[Being an influential doctor in 2026: what are the legal guidelines?]","authors":"Marianne Lahana","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Health influencers are increasingly present on social media, with around 150,000 healthcare professionals involved in France. Their stated goal is to democratize medical information, in a context where 61% of internet users admit to being influenced by this content. In response to this boom, the legal framework has gradually been structured and relaxed. At the same time, ethical regulations remain central. While the principle that medicine cannot be practiced as a business remains firmly established, a notable change has taken place since 2020: doctors can now communicate, provided that the information is accurate, scientifically based, cautious, and devoid of any promotional purpose. The French National Medical Council is exercising increased vigilance and published a charter for responsible content creators in 2025. Physician influencers must therefore reconcile legal and ethical requirements by clearly distinguishing between health information and advertising, ensuring transparency of financial links, and avoiding any commercial incentives. This vigilance could intensify in the future, in the context of European and international discussions on the regulation of online health content.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"377-380"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Infertility, sperm: indicators of overall male health!] 不育、精子：男性整体健康的指标！］
La Revue du praticien Pub Date : 2026-04-01
Louis Bujan
{"title":"[Infertility, sperm: indicators of overall male health!]","authors":"Louis Bujan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"354"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Reasoning and decisionmaking in medicine. Evidence-based medicine. Shared medical decisionmaking. Controversy]. 医学中的推理和决策。循证医学。共同医疗决策。争议)。
La Revue du praticien Pub Date : 2026-04-01
François Blot
{"title":"[Reasoning and decisionmaking in medicine. Evidence-based medicine. Shared medical decisionmaking. Controversy].","authors":"François Blot","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"453-459"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Public health emergencies]. [突发公共卫生事件]。
La Revue du praticien Pub Date : 2026-04-01
Pierre Carli, Caroline Télion
{"title":"[Public health emergencies].","authors":"Pierre Carli, Caroline Télion","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 4","pages":"443-452"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Long-term outcomes of preterm children]. [早产儿的长期结果]。
La Revue du praticien Pub Date : 2026-03-01
Ludovic Tréluyer
{"title":"[Long-term outcomes of preterm children].","authors":"Ludovic Tréluyer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Long-term outcomes of preterm children are one of the major challenges in neonatology. Neurodevelopmental disorders are common in these children. Severe motor, cognitive or neurosensory disorders mainly affect the most immature children. Minor difficulties are present in more than a third of children, whatever their gestational age. School integration is frequently affected, and recourse to developmental support is important. A combination of certain factors should alert caregivers to the risk of neurodevelopmental disorders. These include male gender, small for gestational age, high-grade intraventricular hemorrhage, cystic periventricular leukomalacia or bronchopulmonary dysplasia. Early identification of neurodevelopmental disorders makes it possible to provide support for children and their families and to take advantage of the cerebral plasticity of the developing brain.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"76 3","pages":"291-294"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书